Surrozen, Inc.
As of Oct 22, 2026, Surrozen is in Stage 1, the basing phase, now in week 3 (since Oct 6, 2026). It closed at $25.75, 24.6% below its 52-week high and above its 200-day average, which is rising.
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is SRZN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SRZN among Biotechnology61st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …61 | SRZN | Stage 1 · wk 3 | 93 | +59.3% |
Surrozen: quick answers
What stage is Surrozen in?
As of Oct 22, 2026, Surrozen (SRZN) is in Stage 1, the basing phase. It entered Stage 1 on Oct 6, 2026 and is in week 3. What the four stages mean
Is Surrozen in an uptrend?
Not yet. Surrozen is in Stage 1, a base that can come before an uptrend. It trades 3.7% above its 200-day average, which is rising.
How far is Surrozen from its 52-week high?
Surrozen closed at $25.75 on Oct 22, 2026, 24.6% below its 52-week high of $34.13. Its 52-week low is $11.80.
How has Surrozen performed over the past year?
As of Oct 22, 2026, Surrozen is up 85.9% over the past year and up 19.5% so far in 2026.
Which sector and industry is Surrozen in?
Surrozen is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.